Our Team

Jason joined Sanofi Ventures in 2014 with a background in early-stage biotech investing and transactions. Prior to Sanofi, Jason was the Director of Corporate Development at Translate Bio (fka RaNA Therapeutics), a company co-founded by his previous firm Atlas Venture. While at Atlas, Jason was an Associate in the Life Sciences group. Previously, he was a Flagship Ventures Entrepreneurial Fellow, and consulted for the technology transfer company at the University of Cambridge while performing his doctoral research. Before his time at Cambridge, Jason was an analyst at JSB Partners LP, an investment banking firm, focusing on advisory and business development activities in the life sciences space.

Jason’s active investments include Abcuro, AdvanCell, Atalanta Therapeutics, Expansion Therapeutics, Glycomine, ReCode Therapeutics, Rome Therapeutics, Matchpoint Therapeutics, Nura Bio, and Vrata. Previous investments include Escient Pharmaceuticals (acquired by Incyte), Q32 Bio (NASDAQ: QTTB), Icosavax (acquired by AstraZeneca), Kymera Therapeutics (NASDAQ: KYMR), Ovid Therapeutics (NASDAQ: OVID), Science 37 (NASDAQ: SNCE), and Lysosomal Therapeutics Inc. (acquired by Bial). Jason also serves as the Chair of the Board of Trustees of the Buckingham Browne and Nichols school and the Board of Directors of The Magdalene College Foundation.

Jason graduated with honors from Bowdoin College, and holds a Ph.D. from the University of Cambridge.

Laia joined Sanofi Ventures in 2018 with a background in early-stage biotech investing and drug development. Prior to Sanofi, Laia served as Investment Director for Ysios Capital where she led investments and served on the board of multiple early-stage companies.

Earlier in her career, Laia was part of the European New Business Development team of Janssen-Cilag, a pharmaceutical company of the Johnson & Johnson group, where she assessed commercial and scientific licensing-in opportunities. Previously she worked as a researcher in the UK in companies such as Spirogen (now AstraZeneca), Medivir and UCB-Celltech.

Laia's active investments include Eligo Bioscience, Granite Bio, Muna Therapeutics, NodThera, OMass Therapeutics, QurAlis, SpliceBio, T-Therapeutics and Therini Bio. Previous investments and board roles include Lava Therapeutics (LVTX).

Laia graduated in Chemistry from the University of Barcelona, where she also completed a Master in Science and a Ph.D. with honors. Laia holds an M.B.A. from Cambridge Judge Business School, University of Cambridge, where she focused on biotechnology, healthcare and finance.

Cris joined Sanofi Ventures in 2020 as a Partner to lead investments in Digital Health and Artificial Intelligence. He has a 20-year track record of building startups, tech innovation platforms, and healthtech deal making with some of the largest organizations in the world. Prior to Sanofi, Cris was a founding member of Johnson & Johnson Innovation and served as Global Head of Digital Innovation since 2013. He held chief digital and data science responsibilities, driving digital health strategy and new venture partnerships/investments across the Pharmaceutical, Consumer, and Medical Device businesses.​

Previously, Cris led emerging technology programs within research informatics at Novartis for six years. With entrepreneurial DNA, Cris is notably known for his role in the innovation economy since co-founding Ultra Light Startups, one of the largest and oldest startup venture pitch accelerators in the U.S. This platform catalyzed hundreds of companies in Boston, NYC, and Silicon Valley, leading to several acquisitions by major tech companies. Cris was named to the Boston Business Journal's 40 Under 40 list and recognized as a Top 40 Healthcare Transformer by MM&M Magazine.​

Cris currently serves on the boards of Aetion, Carbon Health, Click Tx, Empatica, Medisafe, Nucleai, and Omada. He holds a M.Sc. in Computer Information Sciences from Boston University and a B.S. in Business Administration from Suffolk University.​

Paulina joined Sanofi Ventures in 2022 with a background in early stage biotech investing and company building. Paulina’s active investments include Attovia, Avilar, Latigo, Odyssey, NextPoint, Normunity, Nuvig, Tisento, Vrata and ZagBio. Prior investments include Aliada Therapeutics (acquired by Abbvie).

Prior to joining Sanofi, Paulina was a Principal on the investment team at Omega Funds. While there Paulina incubated and served as the founding investor for Scorpion Therapeutics (acquired by Eli Lilly). Paulina’s investments also included Arrakis, IFM, Ikena (NASDAQ: IKNA), Synthekine, Theseus (NASDAQ: THRX), and Vanqua Bio.

Paulina began her career with Polaris Partners. Paulina served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics (NASDAQ: CAMP), where she was the Founding CEO. Paulina completed her postdoctoral fellowship in Robert Langer’s lab in the Chemical Engineering department at MIT. During her time at MIT, Paulina founded the MIT Postdoctoral Association and served as its President. Paulina also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine and graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team.

Francesc joined Sanofi Ventures in 2024 with a background in early-stage biotech investing, technology transfer, and biotech management. Prior to his role at Sanofi, he spent three years at AdBio Partners, a pan-European venture firm specializing in early-stage therapeutic projects, where he was responsible for scouting and conducting due diligence on new investment opportunities. As one of the first hires in Barcelona, he played a key role in establishing the local office and expanding the fund's presence in the region.

Earlier in his career, Francesc served as an operational manager at Kiji Therapeutics, an emerging gene and cell therapy company, and as an innovation manager at the technology transfer office of the University of Barcelona.

Francesc holds a degree in Biochemistry from the University of Barcelona, where he also completed an MBA with a focus on biotech investments.

In addition to his professional roles, Francesc serves on the therapeutics board of YVC Collective, a network of emerging life sciences venture capital professionals.

Chris joined Sanofi Ventures in 2017 with a background in life science and healthcare consulting. He previously spent three years as a management consultant at L.E.K. consulting where his work focused on corporate strategy, due diligence, commercial launch planning and asset valuation across the pharmaceutical, biotech, R&D and API manufacturing sectors.

Chris currently serves on the Boards of AdvanCell Isotopes, i2O Therapeutics, Minervax, and Sudo Bio, and is a Board observer for Atalanta Therapeutics, Avilar Therapeutics, Matchpoint Therapeutics, and Nextpoint Therapeutics. He also led Sanofi Ventures’ investment in Curevo.

Prior to a postdoctoral fellowship at Harvard University, Chris earned a Ph.D. in Chemistry from the University of North Carolina at Chapel Hill as well as a B.S. in both Biology and Chemistry from Roger Williams University.

Pierre joined Sanofi Ventures in 2024 with a background in biopharma investing. He previously worked as Analyst at Jeito Capital, where his areas of focus included oncology, cardiology, and neuroscience. Prior to Jeito Capital, Pierre worked as Researcher at Smart Immune, clinical-stage startup company developing cell therapies, as well as at Institut Imagine, leading European Center for research on genetic diseases
 
Pierre holds a Life Science Engineer’s degree from AgroParisTech, a MSc and a PhD in Biotechnology and Biotherapies from Université Paris Cité, and an MBA from the Collège des Ingénieurs. Before starting his doctoral program, Pierre was trained at Pasteur Institute and was a visiting student at the Massachusetts Institute of Technology.

Meg joined Sanofi Ventures in 2021 with a background in biotech investing and business development. She previously worked as Director of Business Development at Vertex Pharmaceuticals, where she was part of the External Innovation team. Prior to Vertex, Meg worked at RA Capital, a crossover investment fund, where her areas of focus included rare diseases, genetic therapies, and neuroscience.

Meg currently serves on the Board of Directors for Veralox.

Meg holds a Ph.D. in Neuroscience from Massachusetts Institute of Technology and a B.S. with Honors in Neuroscience from The Pennsylvania State University. She currently sits on the Steering Committee of the New England Venture Network.

Ritika joined Sanofi Ventures in 2023 with a background in Life Sciences investing, and Corporate Development and Strategy. 

She previously worked as a Vice President at Bain Capital Life Sciences, where she was involved in a range of investments, including early-stage inflection capital, growth equity and pharma carve outs. She supported generation of new investment ideas, due diligence, term sheet negotiations and portfolio management. Ritika co-led the diligence process and was on the founding team for two NewCos, including Cerevel. She also co-led Bain Capital Life Sciences’ investments in Nuvalent, Amylyx and Savara Pharmaceuticals.

Prior to joining Bain Capital Life Sciences, Ritika spent several years across different functions at Biogen, most recently as Associate Director of R&D Strategy and Portfolio Leadership. Additionally, Ritika spent time in Global Commercial Strategy, Corporate Development and Strategy, and Research and Development Strategy where she was responsible for M&A landscapes and prioritization, due diligence, corporate growth strategy, therapeutic and disease area strategies, and portfolio prioritization and governance. 

Ritika graduated with high honors from Boston University Healthcare Management Program. She received an MS in Molecular Biology from the Internal Max Planck Research School at University of Göttingen.

Over the last decade, Alba has worked with some of the world's largest organizations in their digital transformation, enabling them to create new growth engines, by investing into, and partnering with the startup ecosystem. 

Prior to Sanofi, Alba was the Global Head of Innovation Strategy for Venture Capital firm 500 Global, one of the most active early-stage investors in the world, where she was responsible for the firm's end-to-end enterprise deal making. Previously, Alba was a senior management consultant with Deloitte Venture Support, serving as an advisor to Japan’s largest enterprises, helping them source, diligence, invest in, and partner with startups.

Alba holds a Ph.D. in Innovation and Technology Management by the University of Tokyo and an M.Sc. in Biotechnology from the Polytechnical University of Valencia.

Frédérique joined Sanofi Ventures in April 2025. She previously worked in various departments at Sanofi for nearly 25 years, including Global Marketing, Early Development in R&D, and Partnering BD&L Operations.
 
Frédérique holds a post-graduate certificate in Executive Management and has a Bachelor's degree in Office Management.
 
She likes sports, music, nature, cooking, cinema, and spending time at home with her 3 children and family.

Anne joined Sanofi Ventures in May 2023. She previously worked in various departments over the last 19 years including Digital Vaccines, business development and global digital. Anne holds a Bachelors of Science in Business Administration degree with concentration in Management. In her spare time, she enjoys the beach, walking, exploring new trails with her husband, twins and two dogs.